Boehringer Ingelheim distinguished as number one Top Employer 2007 by Science Magazine

Boehringer IngelheimBoehringer Ingelheim has been ranked first among the top employers in the pharmaceutical and biopharmaceutical industry according to the 2007 Top Employers survey conducted by Science. Science's annual survey polls employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries. Each company received a ranking on the basis of whether it treats its employees with respect, whether its work-culture values align with employees' personal values, and multiple other factors.

In the past few years that Science has carried out this survey, Boehringer Ingelheim has climbed up in ranking, from 8th place in 2005 to second place last year. This year, Boehringer Ingelheim has reached the top ranking, recognizing the company’s strong commitment to innovative thinking throughout the product pipeline, from the laboratory to the marketplace, while establishing an excellent working environment.

"This success has not been created overnight. Rather, it is a result of decades of Boehringer Ingelheim's dedication to research and innovation as the drivers for producing new and better medicines for patients," states Mikael Dolsten, Executive Vice President Pharma Research at Boehringer Ingelheim, highlighting the critical importance of innovation. "In a strong science-driven industry, we direct our projects in a climate balancing continuity and change in which we constantly challenge ourselves by seeking a creative dialogue with internal and external experts."

Recruiting the right people, inculcating them with the corporation's values, providing them with scientific challenges, and including them in discussion of the company’s goals have played major roles in Boehringer Ingelheim's success.

"Our process started in the early 1990s, when we developed a corporate vision which was reloaded in 2004 with a concept called 'Lead and Learn'", explains Hans-Joachim Geppert, head of Human Resources at Boehringer Ingelheim. "The guiding principles of this vision have resulted in a great culture of trust and loyalty among our employees, who remain with the company for an exceptional average of 13 years" he adds.

This year's Science survey identified 19 additional companies to represent the top 20 of the best employers from the list of 477 companies in the biotechnology and pharmaceutical industry.

Equally attractive to current and would-be employees, Boehringer Ingelheim's management aims for nimbleness in its operations. Dolsten points out that "the company has the critical mass and resources to discover new innovative drugs and, at the same time, strives to be a simple, dynamic and efficient global organisation".

Science's 2007 Top Employers Survey
Respondents to the Science Top Employer web-based survey are asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change, and a research-driven environment. Survey respondents were asked to write in the names of companies they considered best, average and worst employers. They then rated these companies on 23 different attributes. Attribute categories included Corporate Image, Leadership and Direction, Financial Prowess, Work Culture/Environment, Work/Life Balance, Academics and Collegial Exchange, and Compensation and Benefits. Survey responses were analyzed by Senn-Delaney Culture Diagnostics & Measurement, which used a mathematical process to assign a unique score to rate the companies’ employer reputation.

The report is based on a total sample of 3,157 people in the industry. Nearly one-third (29%) of participants came from outside the United States - primarily Western Europe. Details of the survey results and individual company rankings will be published in the 12 October 2007 issue of Science.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For further information, visit www.boehringer-ingelheim.com.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...